JOP20190282A1 - مركبات وتركيبات لحث تكوّن الغضاريف - Google Patents

مركبات وتركيبات لحث تكوّن الغضاريف

Info

Publication number
JOP20190282A1
JOP20190282A1 JOP/2019/0282A JOP20190282A JOP20190282A1 JO P20190282 A1 JOP20190282 A1 JO P20190282A1 JO P20190282 A JOP20190282 A JO P20190282A JO P20190282 A1 JOP20190282 A1 JO P20190282A1
Authority
JO
Jordan
Prior art keywords
compounds
compositions
inducing
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
JOP/2019/0282A
Other languages
English (en)
Inventor
Zhicheng Wang
Hank Michael James Petrassi
Bao Nguyen
Ha-Soon Choi
Jiqing Jiang
James Paul Lajiness
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190282A1 publication Critical patent/JOP20190282A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Abstract

يتعلق الاختراع الحالي بمركب بالصيغة (I) أو ملح مقبول صيدلانياً منه؛ صورة I أو ملح مقبول صيدلانياً، مركب صنوي، أو أيزومر فراغي منه، حيث تكون المتغيرات كما تم تحديدها في هذه الوثيقة. يقدم الاختراع الحالي أيضاً تركيبات صيدلانية تشتمل على هذه المركبات؛ وطرق لاستخدام هذه المركبات لمعالجة تلف المفاصل أو إصابة في كائن ثديي، لحث إنتاج غضروف زجاجي أو لحث تمايز خلية أولية مولدة للغضروف في خلايا غضروفية ناضجة.
JOP/2019/0282A 2017-06-09 2017-06-16 مركبات وتركيبات لحث تكوّن الغضاريف JOP20190282A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09

Publications (1)

Publication Number Publication Date
JOP20190282A1 true JOP20190282A1 (ar) 2019-12-05

Family

ID=62837959

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0282A JOP20190282A1 (ar) 2017-06-09 2017-06-16 مركبات وتركيبات لحث تكوّن الغضاريف

Country Status (35)

Country Link
US (3) US11091499B2 (ar)
EP (3) EP3915994B9 (ar)
JP (2) JP7229945B2 (ar)
KR (1) KR102656524B1 (ar)
CN (1) CN110719913B (ar)
AR (1) AR113227A1 (ar)
AU (1) AU2018279306C1 (ar)
BR (1) BR112019025866A2 (ar)
CA (1) CA3063985A1 (ar)
CL (1) CL2019003564A1 (ar)
CO (1) CO2019013706A2 (ar)
CR (1) CR20190551A (ar)
CU (1) CU24577B1 (ar)
DK (1) DK3915994T3 (ar)
DO (1) DOP2019000305A (ar)
EA (1) EA201992858A1 (ar)
EC (1) ECSP19086712A (ar)
FI (1) FI3915994T3 (ar)
HR (1) HRP20240155T1 (ar)
IL (2) IL300755A (ar)
JO (1) JOP20190282A1 (ar)
LT (1) LT3915994T (ar)
MA (2) MA57022B1 (ar)
MX (1) MX2019014757A (ar)
NZ (1) NZ759434A (ar)
PE (1) PE20200403A1 (ar)
PH (1) PH12019502764A1 (ar)
PT (1) PT3915994T (ar)
RS (1) RS65161B1 (ar)
SA (1) SA519410729B1 (ar)
SI (1) SI3915994T1 (ar)
TW (1) TWI782036B (ar)
UY (1) UY37759A (ar)
WO (1) WO2018225009A1 (ar)
ZA (1) ZA201907358B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190282A1 (ar) * 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
US20220071972A1 (en) * 2018-12-06 2022-03-10 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015736A (zh) * 2018-12-06 2021-06-22 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
US6407250B1 (en) 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7595327B2 (en) 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
WO2008008884A2 (en) 2006-07-12 2008-01-17 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
KR20120028867A (ko) 2009-04-02 2012-03-23 알러간, 인코포레이티드 프로스타글란딘 ｅ 수용체 길항제
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (en) 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
CN105228626A (zh) * 2013-03-15 2016-01-06 加州生物医学研究所 用于诱导软骨形成的化合物和方法
UY36118A (es) * 2014-05-13 2016-01-08 Novartis Ag Compuestos y composiciones para inducir condrogénesis
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
JOP20190282A1 (ar) * 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف

Also Published As

Publication number Publication date
PT3915994T (pt) 2024-02-15
CA3063985A1 (en) 2018-12-13
CR20190551A (es) 2020-01-28
JP7432778B2 (ja) 2024-02-16
KR20200013046A (ko) 2020-02-05
ZA201907358B (en) 2022-04-28
UY37759A (es) 2019-01-31
MA57022B1 (fr) 2024-02-29
AU2018279306B2 (en) 2020-07-09
JP7229945B2 (ja) 2023-02-28
US20210347784A1 (en) 2021-11-11
JP2020522550A (ja) 2020-07-30
IL300755A (en) 2023-04-01
CU20190098A7 (es) 2020-10-20
AU2018279306A1 (en) 2019-12-05
SA519410729B1 (ar) 2022-07-03
CO2019013706A2 (es) 2020-04-01
PH12019502764A1 (en) 2020-07-13
EP3634967A1 (en) 2020-04-15
EP3915994B9 (en) 2024-02-28
IL271154B1 (en) 2023-03-01
JP2023062064A (ja) 2023-05-02
US11753416B2 (en) 2023-09-12
HRP20240155T1 (hr) 2024-04-12
EP4299123A3 (en) 2024-04-03
CN110719913A (zh) 2020-01-21
EP3915994A1 (en) 2021-12-01
CN110719913B (zh) 2022-10-28
MA50547A (fr) 2020-09-16
WO2018225009A1 (en) 2018-12-13
RU2019144107A3 (ar) 2021-07-30
RS65161B1 (sr) 2024-02-29
US20210079010A1 (en) 2021-03-18
CL2019003564A1 (es) 2020-06-19
DK3915994T3 (da) 2024-02-19
AR113227A1 (es) 2020-02-19
TWI782036B (zh) 2022-11-01
BR112019025866A2 (pt) 2020-07-14
PE20200403A1 (es) 2020-02-26
IL271154B2 (en) 2023-07-01
TW201902900A (zh) 2019-01-16
MX2019014757A (es) 2020-02-12
LT3915994T (lt) 2024-02-26
ECSP19086712A (es) 2019-12-27
US11091499B2 (en) 2021-08-17
DOP2019000305A (es) 2019-01-15
AU2018279306C1 (en) 2021-01-14
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (en) 2023-11-22
NZ759434A (en) 2024-01-26
RU2019144107A (ru) 2021-07-09
KR102656524B1 (ko) 2024-04-12
EP4299123A2 (en) 2024-01-03
US20230365580A1 (en) 2023-11-16
CU24577B1 (es) 2022-02-04
FI3915994T3 (fi) 2024-02-14
IL271154A (en) 2020-01-30
SI3915994T1 (sl) 2024-03-29

Similar Documents

Publication Publication Date Title
PH12016502005A1 (en) Compounds and compositions for inducing chondrogenesis
PH12019502764A1 (en) Compounds and compositions for inducing chondrogenesis
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
MX2019003829A (es) Compuestos de benzo[b]tiofeno como agonistas de sting.
MX2019005244A (es) Acidos propionicos 3-sustituidos como inhibidores de la integrina alfa v.
MX354175B (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2023005099A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
IN2014DN09352A (ar)
MX347544B (es) Antagonista de acido lisofostatidico 1 (lpa1) policiclico y usos del mismo.
WO2017177004A8 (en) Tertiary amides and method of use
IN2014DN09347A (ar)
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2021012357A (es) Proceso para preparar compuestos de acido carbamoiloximetil triazol ciclohexilico.
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
MX2022004742A (es) Derivados del acido carboxilico de quinolona.
MX2017011652A (es) (indazol-4-il)hexahidropirrolopirrolones y metodos de uso.